SANWA KAGAKU KENKYUSHO CO., LTD.

SANWA KAGAKU KENKYUSHO CO., LTD. logo
πŸ‡―πŸ‡΅Japan
Ownership
Subsidiary
Established
1953-01-01
Employees
-
Market Cap
-
Website
http://www.skk-net.com

Phase 3 Study of SK-1403

Phase 3
Completed
Conditions
Interventions
First Posted Date
2019-01-14
Last Posted Date
2020-03-09
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
153
Registration Number
NCT03801980
Locations
πŸ‡―πŸ‡΅

Investigational site (there may be other sites in this country), Tokyo, Japan

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-08-13
Last Posted Date
2020-03-09
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
157
Registration Number
NCT03626948
Locations
πŸ‡―πŸ‡΅

Investigational site (there may be other sites in this country), Tokyo, Japan

Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

Phase 2
Completed
Conditions
Interventions
First Posted Date
2017-07-21
Last Posted Date
2019-03-15
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
58
Registration Number
NCT03226171
Locations
πŸ‡―πŸ‡΅

Investigational site (there may be other sites in this country), Tokyo, Japan

A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus

First Posted Date
2017-07-14
Last Posted Date
2019-03-08
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
269
Registration Number
NCT03218501
Locations
πŸ‡―πŸ‡΅

Investigational site (there may be other sites in this country), Tokyo, Japan

Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

First Posted Date
2017-04-14
Last Posted Date
2018-04-13
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
125
Registration Number
NCT03116191
Locations
πŸ‡―πŸ‡΅

Investigational site (there may be other sites in this country), Tokyo, Japan

Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-08-25
Last Posted Date
2016-10-14
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
6
Registration Number
NCT02878096
Locations
πŸ‡¬πŸ‡§

Quotient Clinical, Ruddington, Nottingham, United Kingdom

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1405

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-07-27
Last Posted Date
2016-11-23
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
6
Registration Number
NCT02846181
Locations
πŸ‡¬πŸ‡§

Quotient Clinical Ltd., Nottingham, United Kingdom

A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-01-08
Last Posted Date
2016-04-12
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Registration Number
NCT02650076
Locations
πŸ‡¬πŸ‡§

Hammersmith Medicines Research, London, United Kingdom

Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout

First Posted Date
2014-12-30
Last Posted Date
2017-04-12
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
60
Registration Number
NCT02327754
Locations
πŸ‡―πŸ‡΅

Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Aichi, Japan

A Study to Evaluate Efficacy and Safety of Methacholine Chloride Challenge Test in Diagnosis of Adult Asthma

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-03-31
Last Posted Date
2014-11-17
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Registration Number
NCT02100267
Locations
πŸ‡―πŸ‡΅

Showa University Clinical Research Center, Setagaya-ku, Tokyo, Japan

Β© Copyright 2024. All Rights Reserved by MedPath